University of Oulu

Aino Rajamäki, Kaisa Sunela, Roosa E. I. Prusila, Milla E. L. Kuusisto, Santiago Mercadal, Tuomas Selander, Hanne Kuitunen, Marjukka Pollari, Esa Jantunen, Ilja Nystrand, Juan-Manuel Sancho, Marc Sorigue & Outi Kuittinen (2021) Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months, Leukemia & Lymphoma, 62:7, 1639-1647, DOI: https://doi.org/10.1080/10428194.2021.1872073

Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months

Saved in:
Author: Rajamäki, Aino1,2; Sunela, Kaisa3; Prusila, Roosa E. I.4;
Organizations: 1Department of Oncology, Central Finland Central Hospital, Jyväskylä, Finland
2Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, Kuopio, Finland
3Department of Oncology, Tays Cancer Center, Tampere University Hospital, Tampere, Finland
4Medical Research Centre and Cancer and Translational Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland
5Department of Haematology, Oulu University Hospital, Oulu, Finland
6ICO-Hospital Duran I Reynals,L’Hospitalet, Spain
7Science Service Center, Kuopio University Hospital, Kuopio, Finland
8Department of Oncology, Oulu University Hospital, Oulu, Finland
9Department of Medicine, Kuopio University Hospital, Kuopio, Finland
10Department of Medicine, North Carelia Central Hospital, Joensuu, Finland
11Research Program Unit, Medical Faculty, University of Helsinki, Finland
12Department of Hematology, ICO-Hospital Germans Trias i Pujol, Functional cytomics-IJC, Badalona, Spain
13Department of Oncology, Kuopio University Hospital, Kuopio, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 2.2 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2021102151898
Language: English
Published: Informa, 2021
Publish Date: 2021-10-21
Description:

Abstract

Findings regarding the role of sex in follicular lymphoma (FL) are contradictory and the prognostic value of sex among patients with early progression of disease (POD) remains unclear. We collected real-life data from nine hospitals in Finland and Spain including 1020 FL patients to study the influence of sex on disease outcome. The median follow-up duration was 67 months (range 0–226 months). Female patients showed better progression-free survival (PFS) (hazard ratio [HR], 0.720; 95% confidence interval [CI], 0.588–0.881), disease-specific survival (DSS) (HR, 0.653; 95% CI, 0.448–0.951), and overall survival (OS) (HR, 0.653; 95% CI, 0.501–0.853) than male patients. However, there were no significant sex differences in prognosis in patients with early POD. This study strengthens the understanding that male sex is an adverse prognostic factor for FL. However, this difference does not apply to patients with early POD.

see all

Series: Leukemia & lymphoma
ISSN: 1042-8194
ISSN-E: 1029-2403
ISSN-L: 1042-8194
Volume: 62
Issue: 7
Pages: 1639 - 1647
DOI: 10.1080/10428194.2021.1872073
OADOI: https://oadoi.org/10.1080/10428194.2021.1872073
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
sex
Copyright information: © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed,or built upon in any way.
  https://creativecommons.org/licenses/by-nc-nd/4.0/